Union européenne - letton - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Union européenne - letton - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Union européenne - letton - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Union européenne - letton - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - multiple mieloma - antineoplastiski līdzekļi - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Union européenne - letton - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - lenalidomide - multiple myeloma; lymphoma, mantle-cell; myelodysplastic syndromes - imūnsupresanti - vairākas myelomarevlimid kā monotherapy ir norādīts tehniskās apkopes ārstēšanai pieaugušiem pacientiem, kuriem nesen diagnosticēta multiplā mieloma, kam ir veikta autologo cilmes šūnu transplantācijas. revlimid kā kombinēto terapiju ar deksametazona, vai bortezomib un deksametazona, vai melfalānu un prednizonu (skatīt 4. iedaļu. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. revlimid kopā ar deksametazona ir indicēts, lai ārstētu multiplā mieloma pieaugušo pacientiem, kuri ir saņēmuši vismaz vienu pirms terapijas. mielodisplastiskais syndromesrevlimid kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar asins pārliešanu atkarīgas no anēmijas dēļ zemas vai vidējas-1-riska mielodisplastiskais sindromi, kas saistīti ar atsevišķu dzēšanu 5q cytogenetic anomālija, kad citi terapijas iespējas ir nepietiekamas vai neatbilstošas. apmetņa šūnu lymphomarevlimid kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed vai ugunsizturīgu apvalku šūnu limfomas. folikulu lymphomarevlimid kopā ar rituksimaba (anti-cd20 antivielu) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš apstrādāts folikulu limfomas (1. pakāpe – 3a).

Union européenne - letton - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomīds - multiple mieloma - imūnsupresanti - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Union européenne - letton - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiplā skleroze - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Union européenne - letton - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridīns - multiplā skleroze - other nervous system drugs - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Union européenne - letton - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Union européenne - letton - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).